Research programme: synthetic antimicrobial peptidomimetics - Lytix Biopharma

Drug Profile

Research programme: synthetic antimicrobial peptidomimetics - Lytix Biopharma

Alternative Names: LTX100; LTX200

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lytix Biopharma
  • Class Amino acids peptides and proteins
  • Mechanism of Action Cell membrane modulators; Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Bacterial infections; Mycoses

Highest Development Phases

  • No development reported Bacterial infections; Mycoses

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Norway (Topical)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in Norway (Topical)
  • 04 Feb 2011 Research programme: synthetic antimicrobial peptidomimetics - Lytix Biopharma is available for licensing as of 23 Oct 2006. http://www.lytixbiopharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top